| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:38 | Dividenden-Garant Sanofi: Milliarden-Deal an Weihnachten | 405 | Der Aktionär | Der französische Pharma-Konzern Sanofi bleibt aktiv in Sachen Übernahmen. An Heiligabend kündigte die Gesellschaft die milliardenschwere Akquisition von Dynavax Technologies an, womit das Impfstoff-Business... ► Artikel lesen | |
| 08:27 | Sanofi kauft Dynavax Technologies für 2,2 Mrd US-Dollar | 404 | Dow Jones News | DJ Sanofi kauft Dynavax Technologies für 2,2 Mrd US-Dollar
DOW JONES--Der französische Pharmakonzern Sanofi übernimmt das US-Impfstoffunternehmen Dynavax Technologies Corporation zum Wert von 2... ► Artikel lesen | |
| 14:58 | XFRA UP0: AUSSETZUNG/SUSPENSION | 220 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILULTRAGENYX PHARM.... ► Artikel lesen | |
| 15:41 | XFRA UP0: WIEDERAUFNAHME/RESUMPTION | 203 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 15:24 | Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs | 180 | AFX News | BRUSSELS (dpa-AFX) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such... ► Artikel lesen | |
| 14:18 | Genmab A/S: Genmab Portfolio Prioritization Update | 179 | Business Wire | Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher-impact opportunities across Genmab's... ► Artikel lesen | |
| 14:06 | ARS Pharmaceuticals, Inc.: neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) | 124 | GlobeNewswire (Europe) | neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (- 30 kg) living with severe allergic reactions Pediatrix Therapeutics- which has... ► Artikel lesen | |
| 14:06 | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | 115 | GlobeNewswire (Europe) | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| 13:36 | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | 64 | GlobeNewswire (Europe) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| VIATRIS | 10,500 | 0,42 | +4,00 % | 0,12 | 24.11.2025 | |
| AMGEN | 281,90 | 8,08 | +2,87 % | 2,52 | 13.02.2026 | |
| ROYALTY PHARMA | 33,350 | 0,76 | +2,28 % | 0,22 | 14.11.2025 | |
| REGENERON PHARMACEUTICALS | 660,20 | 3,04 | +0,46 % | 0,88 | 20.11.2025 | |
| IONIS PHARMACEUTICALS | 67,42 | 0,00 | 0,00 % | |||
| BIOGEN | 150,90 | 0,00 | 0,00 % | |||
| VERA THERAPEUTICS | 51,51 | 0,00 | 0,00 % | |||
| LENZ THERAPEUTICS | 16,790 | 0,00 | 0,00 % |
| Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
|---|---|---|---|---|---|
| 10X GENOMICS INC A2PPQJ Tradegate | 13,800 14,010 | -0,210 -1,50 % | 07:32 | ||
| 4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 7,760 7,975 | -0,215 -2,70 % | 16:41 | ||
| AARDVARK THERAPEUTICS INC A412BL NASDAQ | 13,520 13,670 | -0,150 -1,10 % | 16:40 | ||
| ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 3,011 3,135 | -0,124 -3,96 % | 16:12 | ||
| ABIVAX SA ADR A3EWCP Tradegate | 121,000 118,00 | +3,00 +2,54 % | 16:36 | ||
| ABSCI CORPORATION A3CVW3 NASDAQ | 3,490 3,570 | -0,080 -2,24 % | 16:41 | ||
| AC IMMUNE SA A2AR5F Tradegate | 2,730 2,665 | +0,065 +2,44 % | 16:38 | ||
| ACADIA PHARMACEUTICALS INC 603035 Tradegate | 23,000 23,610
| -0,610 -2,58 % | 16:12 | ||
| ACLARIS THERAPEUTICS INC A1412H Tradegate | 2,554 2,464 | +0,090 +3,65 % | 15:26 | ||
| ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 13,985 14,215 | -0,230 -1,62 % | 15:36 |